Nimotuzumab is a humanized mAb for the treatment of EGFR over-expressing tumors and has been used with success in advanced unresectable locoregional HNSCC patients (Basavaraj et al., 2010; Reddy et al., 2014). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.